ClinicalTrials.gg
TerminatedNCT00430716Updated Dec 22, 2020Results posted

To Assess The Efficacy and Safety Of Oral Sildenafil in the Treatment of Pulmonary Arterial Hypertension.

A Phase 4 interventional study of Sildenafil citrate and Sildenafil citrate in Pulmonary Arterial Hypertension, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Terminated at 46 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-22.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment

Why this study was terminated
This study was terminated at the recommendation of an independent Data Monitoring Committee. The decision was not based on any safety concerns.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
130
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies testing sildenafil in Pulmonary Arterial Hypertension — 1 open to participants now, 1 under way, 1 of them phase 3. sildenafil · Pulmonary Arterial Hypertension.

Enrollment
4th of 18
130 · median 23
Started
2008
with 1 other
Phase 4
6 of 18
none open now
Registered
6th of 18
by date
Lead sponsor
7 of 18
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 18 studies testing sildenafil in Pulmonary Arterial Hypertension, this one is the 4th largest by enrollment, is one of 2 that started in 2008, is one of 6 in phase 4, and was the 6th registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 140 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

1 of the 18 studies testing sildenafil in Pulmonary Arterial Hypertension is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About sildenafil

sildenafil: first FDA approval 1998 (VIAGRA), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing sildenafil in Pulmonary Arterial Hypertension, or all of them as a file.
02

Study summary

To demonstrate a dose response for 1 mg, 5 mg and 20 mg TID oral sildenafil for the treatment of subjects with PAH.

03

Conditions studied

  • Pulmonary Arterial Hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with PAH (i.e. IPAH or secondary to connective tissue disease or with surgical repair of ASD, VSD, PDA, aorto-pulmonary window) whose baseline six minute walk test distance is >/= 100 m and \</= 450 m.
  • Subjects with a mean pulmonary artery pressure of >/= 25 mmHg and a pulmonary artery wedge pressure of \</= 15 mmHg at rest via right heart catheterization performed within 12 weeks prior to randomization.

Exclusion criteria

Exclusion Criteria:

  • Subjects whose 6 Minute Walk Distance may be limited by conditions other than PAH related dyspnoea or fatigue, e.g. claudication from vascular insufficiency or significant arthritis.
  • Subjects who are currently receiving any forms of chronic treatment for PAH such as prostacyclin, PDE-5 inhibitors, endothelin-receptor antagonists, nitrates or nitric oxide donors (e.g. arginine supplement, nicorandil) in any form, protease inhibitors such as ritonavir and saquinavir, ketoconazole, itraconazole, and alpha blockers. Subjects previously receiving any of these drugs must have stopped use for a period of at least 1 month prior to screening, except in the case of bosentan or prostacyclin (3 months).
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
130 participants (actual)

Study arms

  • Experimental
    Sildenafil High dose

    Drug: Sildenafil citrate

  • Experimental
    Sildenafil Low dose

    Drug: Sildenafil citrate

  • Experimental
    Sildenafil medium dose

    Drug: Sildenafil citrate

  • Experimental
    Sildenafil - Open label Phase

    Open label extension from week 12 to week 24.

    Drug: Sildenafil citrate

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Total Distance Walked During 6-Minute Walk Test (6MWT) at Week 12

    6 MWT was the distance that a participant could walk in 6 minutes. Participants were asked to perform the test at a pace that was comfortable to them, with as many breaks as they needed. Continuous pulse oximetry was conducted during the test for safety.

    Time frame: Baseline and Week 12

Secondary outcomes

  1. Change From Baseline in Mean Pulmonary Arterial Pressure (mPAP) at Week 12

    mPAP was measured using a pressure transducer positioned at the mid-axillary line.

    Time frame: Baseline and Week 12

  2. Number of Participants With Clinical Worsening

    Clinical worsening was defined as death; or lung transplantation; or hospitalization due to pulmonary hypertension; or initiation of prostacyclin therapy; or initiation of endothelin receptor antagonist therapy. (PAH=pulmonary arterial hypertension) Due to very low number of events of clinical worsening reported, the median days to clinical worsening could not be estimated.

    Time frame: Baseline through Week 12

  3. Number of Participants With Change From Baseline in PAH Criteria for Functional Capacity and Therapeutic Class at Week 12

    Pulmonary arterial hypertension (PAH) Criteria for WHO Class: Class I (Participants without resulting limitation of physical activity);Class II (Participants with slight limitation of physical activity though comfortable at rest);Class III (Participants with marked limitation of physical activity,though comfortable at rest);Class IV(Participants with inability to carry out any physical activity without symptoms,manifest signs of right heart failure; dyspnoea and/or fatigue may even be present at rest; and discomfort is increased by any physical activity).

    Time frame: Baseline and Week 12

  4. Change From Baseline in B-Type Natriuretic Peptide (BNP) at Week 12

    BNP is a non-invasive biomarker and an indicator of progression of PAH/ right ventricular dysfunction in participants with PAH.

    Time frame: Baseline and Week 12

  5. Change From Baseline in Pro-BNP at Week 12

    Pro- BNP which is a precursor of BNP, is a non-invasive biomarker and an indicator of progression of PAH / RV dysfunction in participants with PAH.

    Time frame: Baseline and Week 12

  6. Change From Baseline in TAPSE Measurement at Week 12

    Tricuspid annular plane systolic excursion (TAPSE) was measured as the total displacement of the tricuspid annulus in cm from end diastole to end systole.TAPSE is an indicator of progression of PAH /right ventricular dysfunction. The baseline data for 33 participants were measured incorrectly and the results from the 33 participants (both baseline and post-baseline) were excluded from the analysis.

    Time frame: Baseline and Week 12

  7. Change From Baseline in BORG Dyspnoea Score at Week 12

    BORG dyspnoea scale is a 10-point scale where following scores stands for severity of dyspnoea: 0 (no breathlessness at all); 0.5 (very very slight \[just noticeable\]); 1 (very slight); 2 (slight breathlessness); 3 (moderate); 4 (some what severe); 5 (severe breathlessness); 7 (very severe breathlessness); 9 (very very severe \[almost maximum\] and 10 (maximum).

    Time frame: Baseline and Week 12

07

Results

Posted May 17, 2011
Limitations and caveats
The trial was not designed to demonstrate the equivalence of doses and due to premature study termination, the resulting sample size was not adequately powered to show superiority.

Participant flow

Double Blind Phase
Participant flow — Double Blind Phase
MilestoneSildenafil 1 mgSildenafil 5 mgSildenafil 20 mg
Started424345
Treated414345
Completed363839
Not completed656
Withdrew: Death100
Withdrew: No longer willing to participate211
Withdrew: Other020
Withdrew: Study terminated by sponsor112
Withdrew: Adverse event113
Withdrew: Not treated100
Open Label Phase
Participant flow — Open Label Phase
MilestoneSildenafil 1 mgSildenafil 5 mgSildenafil 20 mg
Started363839
Completed273132
Not completed977
Withdrew: Lost to follow-up101
Withdrew: No longer willing to participate011
Withdrew: Other311
Withdrew: Protocol violation100
Withdrew: Study terminated by sponsor454

Outcome measures

PrimaryChange From Baseline in the Total Distance Walked During 6-Minute Walk Test (6MWT) at Week 12

6 MWT was the distance that a participant could walk in 6 minutes. Participants were asked to perform the test at a pace that was comfortable to them, with as many breaks as they needed. Continuous pulse oximetry was conducted during the test for safety.

Time frame:
Baseline and Week 12
Reported as:
Mean · Meters
Change From Baseline in the Total Distance Walked During 6-Minute Walk Test (6MWT) at Week 12
MetersSildenafil 1 mgSildenafil 5 mgSildenafil 20 mg
Change From Baseline in the Total Distance Walked During 6-Minute Walk Test (6MWT) at Week 1214.21 (0.41 to 28.00)40.75 (25.16 to 56.34)38.36 (23.77 to 52.94)
Statistical analysis
  • Sildenafil 1 mg vs Sildenafil 20 mg · ANOVA · p = 0.011 · Mean difference (net): 24.15
  • Sildenafil 5 mg vs Sildenafil 20 mg · ANOVA · p = 0.545 · Mean difference (net): -1.17
SecondaryChange From Baseline in Mean Pulmonary Arterial Pressure (mPAP) at Week 12

mPAP was measured using a pressure transducer positioned at the mid-axillary line.

Time frame:
Baseline and Week 12
Reported as:
Mean · mmHg
Change From Baseline in Mean Pulmonary Arterial Pressure (mPAP) at Week 12
mmHgSildenafil 1 mgSildenafil 5 mgSildenafil 20 mg
Change From Baseline in Mean Pulmonary Arterial Pressure (mPAP) at Week 12-1.73 (-5.99 to 2.54)-3.44 (-5.87 to -1.00)-3.29 (-6.05 to -0.52)
Statistical analysis
  • Sildenafil 1 mg vs Sildenafil 20 mg · ANCOVA · p = 0.278 · Mean difference (net): -2.51 · 95% CI -7.07 to 2.05
  • Sildenafil 5 mg vs Sildenafil 20 mg · ANCOVA · p = 0.846 · Mean difference (net): -0.44 · 95% CI -4.98 to 4.09
SecondaryNumber of Participants With Clinical Worsening

Clinical worsening was defined as death; or lung transplantation; or hospitalization due to pulmonary hypertension; or initiation of prostacyclin therapy; or initiation of endothelin receptor antagonist therapy. (PAH=pulmonary arterial hypertension) Due to very low number of events of clinical worsening reported, the median days to clinical worsening could not be estimated.

Time frame:
Baseline through Week 12
Reported as:
Count of participants · Participants
Number of Participants With Clinical Worsening
ParticipantsSildenafil 1 mgSildenafil 5 mgSildenafil 20 mg
death110
lung transplantation000
hospitalisation due to pulmonary hypertension102
PAH deterioration requiring therapy000
receptor antagonist therapy010
SecondaryNumber of Participants With Change From Baseline in PAH Criteria for Functional Capacity and Therapeutic Class at Week 12

Pulmonary arterial hypertension (PAH) Criteria for WHO Class: Class I (Participants without resulting limitation of physical activity);Class II (Participants with slight limitation of physical activity though comfortable at rest);Class III (Participants with marked limitation of physical activity,though comfortable at rest);Class IV(Participants with inability to carry out any physical activity without symptoms,manifest signs of right heart failure; dyspnoea and/or fatigue may even be present at rest; and discomfort is increased by any physical activity).

Time frame:
Baseline and Week 12
Reported as:
Number · Participants
Number of Participants With Change From Baseline in PAH Criteria for Functional Capacity and Therapeutic Class at Week 12
ParticipantsSildenafil 1 mgSildenafil 5 mgSildenafil 20 mg
Worsened 2 Classes000
Worsened 1 Class132
No Change352735
Improved 1 Class4106
Improved 2 Classes100
Missing032
Statistical analysis
  • Sildenafil 1 mg vs Sildenafil 20 mg · Regression, Logistic · p = 0.448 · Odds ratio (or): 1.55 · 95% CI 0.50 to 4.78
  • Sildenafil 5 mg vs Sildenafil 20 mg · Regression, Logistic · p = 0.897 · Odds ratio (or): 1.08 · 95% CI 0.35 to 3.32
SecondaryChange From Baseline in B-Type Natriuretic Peptide (BNP) at Week 12

BNP is a non-invasive biomarker and an indicator of progression of PAH/ right ventricular dysfunction in participants with PAH.

Time frame:
Baseline and Week 12
Reported as:
Mean · pg/mL
Change From Baseline in B-Type Natriuretic Peptide (BNP) at Week 12
pg/mLSildenafil 1 mgSildenafil 5 mgSildenafil 20 mg
Change From Baseline in B-Type Natriuretic Peptide (BNP) at Week 12-6.28 (-80.75 to 68.19)-53.46 (-99.98 to -6.94)-97.42 (-161.45 to -33.39)
Statistical analysis
  • Sildenafil 1 mg vs Sildenafil 20 mg · ANCOVA · p = 0.005 · Mean difference (net): -104.80 · 95% CI -177.44 to -32.16
  • Sildenafil 5 mg vs Sildenafil 20 mg · ANCOVA · p = 0.496 · Mean difference (net): -25.00 · 95% CI -97.50 to 47.50
SecondaryChange From Baseline in Pro-BNP at Week 12

Pro- BNP which is a precursor of BNP, is a non-invasive biomarker and an indicator of progression of PAH / RV dysfunction in participants with PAH.

Time frame:
Baseline and Week 12
Reported as:
Mean · pg/mL
Change From Baseline in Pro-BNP at Week 12
pg/mLSildenafil 1 mgSildenafil 5 mgSildenafil 20 mg
Change From Baseline in Pro-BNP at Week 12-111.53 (-507.68 to 284.63)-306.76 (-523.82 to -89.70)-428.54 (-676.74 to -180.34)
Statistical analysis
  • Sildenafil 1 mg vs Sildenafil 20 mg · ANCOVA · p = 0.009 · Mean difference (net): -462.12 · 95% CI -807.53 to -116.71
  • Sildenafil 5 mg vs Sildenafil 20 mg · ANCOVA · p = 0.414 · Median difference (net): -141.45 · 95% CI -483.48 to 200.58
SecondaryChange From Baseline in TAPSE Measurement at Week 12

Tricuspid annular plane systolic excursion (TAPSE) was measured as the total displacement of the tricuspid annulus in cm from end diastole to end systole.TAPSE is an indicator of progression of PAH /right ventricular dysfunction. The baseline data for 33 participants were measured incorrectly and the results from the 33 participants (both baseline and post-baseline) were excluded from the analysis.

Time frame:
Baseline and Week 12
Reported as:
Mean · cm
Change From Baseline in TAPSE Measurement at Week 12
cmSildenafil 1 mgSildenafil 5 mgSildenafil 20 mg
Change From Baseline in TAPSE Measurement at Week 120.08 (-0.04 to 0.19)0.17 (0.05 to 0.29)-0.02 (-0.15 to 0.10)
Statistical analysis
  • Sildenafil 1 mg vs Sildenafil 20 mg · ANCOVA · p = 0.890 · Mean difference (net): -0.01 · 95% CI -0.17 to 0.15
  • Sildenafil 5 mg vs Sildenafil 20 mg · ANCOVA · p = 0.124 · Mean difference (net): -0.13 · 95% CI -0.29 to 0.04
SecondaryChange From Baseline in BORG Dyspnoea Score at Week 12

BORG dyspnoea scale is a 10-point scale where following scores stands for severity of dyspnoea: 0 (no breathlessness at all); 0.5 (very very slight \[just noticeable\]); 1 (very slight); 2 (slight breathlessness); 3 (moderate); 4 (some what severe); 5 (severe breathlessness); 7 (very severe breathlessness); 9 (very very severe \[almost maximum\] and 10 (maximum).

Time frame:
Baseline and Week 12
Reported as:
Mean · Units on a scale
Change From Baseline in BORG Dyspnoea Score at Week 12
Units on a scaleSildenafil 1 mgSildenafil 5 mgSildenafil 20 mg
Change From Baseline in BORG Dyspnoea Score at Week 12-0.28 (-0.76 to 0.20)-0.89 (-1.35 to -0.43)-0.43 (-0.94 to 0.08)
Statistical analysis
  • Sildenafil 1 mg vs Sildenafil 20 mg · Wilcoxon (Van-Elteren) · p = 0.382 · Median difference (net): 0.00 · 95% CI -1.00 to 0.00
  • Sildenafil 5 mg vs Sildenafil 20 mg · Wilcoxon (Van-Elteren) · p = 0.141 · Mean difference (net): 0.00 · 95% CI 0.00 to 1.00

Adverse events

Collected over 24 Weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sildenafil 1 mg1/41 (2.4%)6/41 (14.6%)21/41 (51.2%)
Sildenafil 5 mg1/43 (2.3%)3/43 (7%)22/43 (51.2%)
Sildenafil 20 mg0/45 (0%)5/45 (11.1%)22/45 (48.9%)
Most frequent serious events
Showing 10 of 34
Most frequent serious events
EventSildenafil 1 mgSildenafil 5 mgSildenafil 20 mg
Right ventricular failureCardiac disorders0/410/432/45
Atrial flutterCardiac disorders1/410/430/45
Cor pulmonaleCardiac disorders1/410/430/45
HepatitisHepatobiliary disorders1/410/430/45
Lower respiratory tract infectionInfections and infestations1/410/430/45
PneumoniaInfections and infestations1/410/430/45
Atrial flutterCardiac disorders1/410/430/45
Cor pulmonaleCardiac disorders1/410/430/45
HepatitisHepatobiliary disorders1/410/430/45
Lower respiratory tract infectionInfections and infestations1/410/430/45
Most frequent other events
Showing 10 of 199
Most frequent other events
EventSildenafil 1 mgSildenafil 5 mgSildenafil 20 mg
DyspnoeaRespiratory, thoracic and mediastinal disorders2/414/433/45
FatigueGeneral disorders3/411/430/45
DizzinessNervous system disorders3/412/432/45
DyspnoeaRespiratory, thoracic and mediastinal disorders2/413/433/45
HeadacheNervous system disorders2/413/433/45
EpistaxisRespiratory, thoracic and mediastinal disorders1/413/430/45
HeadacheNervous system disorders1/411/433/45
NasopharyngitisInfections and infestations2/411/433/45
Back painMusculoskeletal and connective tissue disorders1/411/433/45
FatigueGeneral disorders2/411/430/45

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Sildenafil 1 mgSildenafil 5 mgSildenafil 20 mgTotal
Mean42.5 ± 16.544.4 ± 17.446.4 ± 17.744.5 ± 17.2
Sex: Female, Male
Sex: Female, Male(Participants)Sildenafil 1 mgSildenafil 5 mgSildenafil 20 mgTotal
Female28332687
Male13101942
08

Study locations

46 sites
  • Arizona Pulmonary Specialists, LTD
    Phoenix, Arizona 85013, United States
  • Medical College of Georgia
    Augusta, Georgia 30912, United States
  • Atlanta Institute for Medical Research, Inc.
    Decatur, Georgia 30030, United States
  • Chicago Heart Institute
    Elk Grove Village, Illinois 60007, United States
  • The Care Group, LLC
    Indianapolis, Indiana 46260, United States
  • The University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27599, United States
  • Mid Carolina Cardiology
    Charlotte, North Carolina 28204, United States
  • Presbyterian Hospital
    Charlotte, North Carolina 28204, United States
  • Baylor College of Medicine Pulmonary Section
    Houston, Texas 77030, United States
  • St. Luke's Episcopal Hospital
    Houston, Texas 77030, United States
  • University of Utah Sciences Center
    Salt Lake City, Utah 84132, United States
  • CJW Chippenham Medical Center
    Richmond, Virginia 23225, United States
  • Pulmonary Associates of Richmond, Inc.
    Richmond, Virginia 23225, United States
  • Virginia Cardiovascular Specialists
    Richmond, Virginia 23225, United States
  • Cardiovascular Associates of Virginia
    Richmond, Virginia 23230, United States
  • Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg
    Leuven, 3000, Belgium
  • Hospital São Lucas da PUCRS
    Porto Alegre, RS 90610-000, Brazil
  • Instituto Dante Pazzanese de Cardiologia
    Sao Paulo, SP 04012-909, Brazil
  • Peta mnogoprofilna bolnitsa za aktivno lechenie, Klinika po kardiologia
    Sofia, 1233, Bulgaria
  • Mnogoprofilna bolnitsa za aktivno lechenie i speshna meditsina "N.I.Pirogov"
    Sofia, 1606, Bulgaria
  • Beijing Shijitan Hospital
    Beijing, 100038, China
  • Shanghai Pulmonology Hospital
    Shanghai, 200433, China
  • Attikon Hospital
    Haidari, Athens 12462, Greece
  • Care Hospital, The Institute of Medical Sciences
    Hyderabad, Andhra Pradesh 500 001, India
  • Mehta Hospital & Cardiopulmonary Care Center
    Ahmedabad, Gujarat 380 054, India
  • Bankers Heart Institute
    Vadodara, Gujarat 390 015, India
  • St. John's Medical College Hospital
    Bangalore, Karnataka 560 034, India
  • Metro Multispeciality Hospital
    Noida, Uttar Pradesh 201301, India
  • IRCCS Policlinico San Matteo
    Pavia, 27100, Italy
  • Unita' di Ipertensione Polmonare, Dipartimento di Scienze Respiratorie e Cardiovascolari
    Roma, 00161, Italy
  • P. Stradins Clinical University Hospital / Latvian Centre of Cardilogy
    Riga, LV - 1002, Latvia
  • National Heart Institute
    Kuala Lumpur, 50400, Malaysia
  • VU Medisch Centrum / afdeling Longziekten
    Amsterdam, 1081 HV, Netherlands
  • Erasmus MC
    Rotterdam, 3015 GE, Netherlands
  • Philippine General Hospital
    Manila City, 1000, Philippines
  • Philippine Heart Center
    Quezon City, 1100, Philippines
  • Krakowski Szpital Specjalistyczny Im. Jana Pawla II w Krakowie
    Krakow, 31-202, Poland
  • Samodzielny Publiczny Zaklad Opieki Zdrowotnej, Slaskie Centrum Chorob Serca
    Zabrze, 41-800, Poland
  • Spitalul Clinic de Boli Infectioase si Pneumoftiziologie Dr. Victor Babes
    Timisoara, Timis, Romania
  • Spitalul Clinic de Pneumoftiziologie
    Iasi, 700115, Romania
  • Scientific Center of Cardiovascular surgery n.a. A.N.Bakoulev RAMS
    Moscow, 117931, Russian Federation
  • Scientific Center of Cardiovascular surgery n.a. A.N.Bakoulev RAMS
    Moscow, 121552, Russian Federation
  • Division of Rheumatology Allergy and Immunology, Department of Medicine, Faculty of Medicine
    Amphoe Mueang, Khon Kaen 40002, Thailand
  • Department of Medicine,
    Bangkok, 10330, Thailand
  • Norfolk and Norwich University Hospital
    Norwich, Norfolk NR4 7UY, United Kingdom
  • Room 224A Sir William Leech Centre
    Newcastle Upon Tyne, Tyne and Wear NE7 7DN, United Kingdom
09

References and documents

Publications

  • Vizza CD, Sastry BK, Safdar Z, Harnisch L, Gao X, Zhang M, Lamba M, Jing ZC. Efficacy of 1, 5, and 20 mg oral sildenafil in the treatment of adults with pulmonary arterial hypertension: a randomized, double-blind study with open-label extension. BMC Pulm Med. 2017 Feb 23;17(1):44. doi: 10.1186/s12890-017-0374-x. PubMed 28228114 ↗

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2008 to primary completion in May 2010, 25 months.

Results were first posted in May 2011, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2007
First posted
Feb 2, 2007
StartActual
Apr 8, 2008
Primary completionActual
May 25, 2010
CompletionActual
May 25, 2010
Results first posted
May 17, 2011
Last update
Dec 22, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00430716
Responsible party
Sponsor
First posted
Feb 2, 2007
Start date
Apr 8, 2008
Primary completion
May 25, 2010
Completion
May 25, 2010
Results posted
May 17, 2011
Last update
Dec 22, 2020

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sildenafil

Start the discussion